A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e118-20. doi: 10.1097/QAI.0000000000000057.

¹ *Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC †Community Research Initiative of New England, Boston, MA ‡Southwest Care Center, Santa Fe, NM §Anthony Mills MD Inc, Los Angeles, CA ‖Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA ¶Orlando Immunology Center, Orlando, FL #Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA **Gilead Sciences, Foster City, CA.

No abstract available

Publication types